Building Trust in RWE Will Support Clearer Regulatory Uses Gregory Daniel Editorial 23 December 2019 Pages: 417 - 419
A Transitional Probability Model for Parkinson’s Disease Motor States With Applications to Missing Data Phillip Dinh Biostatistics: Statistics 23 December 2019 Pages: 420 - 425
Measurement Equivalence of Patient-Reported Outcome Measures Migrated to Electronic Formats: A Review of Evidence and Recommendations for Clinical Trials and Bring Your Own Device Bill ByromChad GwaltneyWillie Muehlhausen Clinical Trials: Commentary 23 December 2019 Pages: 426 - 430
Training on the Use of Technology to Collect Patient-Reported Outcome Data Electronically in Clinical Trials: Best Practice Recommendations from the ePRO Consortium Jenny J. LyMabel CrescioniePRO Consortium Clinical Trials: Commentary 23 December 2019 Pages: 431 - 440
Best Practices for Avoiding Paper Backup When Implementing Electronic Approaches to Patient-Reported Outcome Data Collection in Clinical Trials Cindy HowryCeleste A. ElashTracey Rothrock Clinical Trials: Analytical Report 23 December 2019 Pages: 441 - 445
Comparison of Postdoctoral Pharmacy Training Programs: Drug Information Residencies and Medical Information Fellowships Jimmy GonzalezSamantha BryantEvelyn R. Hermes-DeSantis Educational Perspective: Review Article 23 December 2019 Pages: 446 - 454
Age-Appropriate Pediatric Dosage Forms in Japan: Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation Jumpei SaitoMiki AkabaneYoichi Ishikawa Global Perspectives: Original Article 23 December 2019 Pages: 455 - 471
Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective Kaori KidoNaoki MatsumaruKatsura Tsukamoto Global Perspectives: Original Article 23 December 2019 Pages: 472 - 480
Technology Forecasting for Medical Devices Guidance Formulation: A Case Study in Japan Sayaka ItohShingo Kano Global Perspectives: Analytical Report Open access 23 December 2019 Pages: 481 - 489
The Use of Microblog “Weibo” by Chinese Patent Medicine Companies in China Qirui SongCarolina Oi Lam UngHao Hu Global Perspectives: Original Article 23 December 2019 Pages: 490 - 496
Regulatory Trends in Drug Development in Asia Pacific Fengyun Vicky HanKaren Weiss Global Perspectives: Review Article 23 December 2019 Pages: 497 - 501
Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical Uncertainties Manas A. RaneJennifer G. FosterCharles H. Hennekens Product Safety: Commentary 23 December 2019 Pages: 502 - 505
The Information for the Dosing of Medicinal Products in Different Age Intervals Is Ambiguous Nika ZidaričSamo Kreft Product Safety: Original Article 23 December 2019 Pages: 506 - 511
Risk-Based Monitoring: Key Conditions in Collaboration Between Contract Research Organization and Sponsor Marion WolfsAmy BambicSina Djali Regulatory Science: Original Article 23 December 2019 Pages: 512 - 518
Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting David G. StraussGary GintantPhilip T. Sager Regulatory Science: Meeting Report 23 December 2019 Pages: 519 - 525
Of Straws, Camels, Research Regulation, and IRBs Phoebe FriesenBarbara RedmanArthur Caplan Regulatory Science: Review Article 23 December 2019 Pages: 526 - 534
Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework Katsura TsukamotoMiriam CnopNaoki Matsumaru Regulatory Science: Original Article 23 December 2019 Pages: 535 - 541
Managing the Risks of Medicines: An Examination of FDA’s Application of Criteria for Requiring a REMS Paul J. SeligmanRebekah H. AnguianoKatie Stabi Regulatory Science: Original Article 23 December 2019 Pages: 542 - 548
Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy Donatas StakišaitisKristina Zamarytė-SakavičienėRimas Jonas Jankūnas Value & Access: Original Article 23 December 2019 Pages: 549 - 553